Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the survival of neurons and growth and differentiation of dendrites and axons. The purpose of the present study was to evaluate plasma levels of BDNF of leprosy patients at different stages of multidrug therapy (MDT) in comparison with non-infected individuals. Plasma levels of BDNF were measured by ELISA in 30 healthy controls and 37 leprosy patients at diagnosis, during and after MDT. Plasma levels of BDNF tended to be higher in control subjects in comparison with leprosy patients, but this difference does not reach statistical significance. Interestingly, BDNF levels changed following MDT, achieving statistical difference only at the 2 nd dose of MDT. These results indicate that BDNF may not be a surrogate marker of leprosy infection and/or related neuropathy. Further research is needed to investigate the meaning of BDNF level changes following leprosy treatment. Key words: leprosy, BDNF, peripheral neuropathy, biomarker, follow-up.
Leprosy is a contagious, granulomatous and chronic infectious disease caused by Mycobacterium leprae, an obligate intracellular bacillus that affects mainly the skin and peripheral nerves [1] [2] [3] . It can be better understood when regarded as an association of two diseases: first, a chronic infection that induces a cell-mediated immune response; second, a peripheral neuropathy which is triggered by infection and followed by a series of immunological events, whose evolution, sequels and disabilities often last many years, even after infection has ceased [4] [5] [6] [7] . Leprosy still remains the commonest cause of peripheral neuropathy in developing countries 8 . A recent important contribution to the understanding of leprosy pathogenesis has been the elucidation of the molecular basis for the entry of M. leprae into the Schwann cells and the peripheral nerve. The demonstration of rapid demyelination and axonal atrophy induced by M. leprae provides a model for elucidating the molecular events of early nerve degeneration which might be common to neurodegenerative diseases of both infectious and unknown etiology [9] [10] [11] [12] . In addition, M. leprae may directly induce Schwann cells to secrete metalloproteinases independent of the extent of inflammation in leprous neuropathy 13 . Neurotrophins are soluble polypeptide molecules that act on neurons of the central and peripheral nervous system (PNS), being involved in their survival and differentiation. These molecules also help stimulate and control neurogenesis, the brain-derived neurotrophic factor (BDNF) being one of the most active 14, 15 . According to several reports on neurodegenerative disorders, neurotrophin levels generally differ from those found in healthy subjects. For instance, several studies have shown altered circulating levels of BDNF in Alzheimer's disease, Parkinson's disease and schizophrenia 16, 17 . Gagliard 18 studied diabetic peripheral neuropathy and reported that the patients' capacity to maintain the normal structure and function of their nerves may depend on the expression and effectiveness of these neurotrophins.
It is known that BDNF is synthesized by a wide variety of cells and tissues, including Schwann cells, and has different modulating functions in the PNS myelination program, with highly specific regulated mechanisms of action 19 . The role of neurotrophins in peripheral neuropathies, including leprosy, still remains open 20 . Circulating levels of BDNF of leprosy patients have not been assessed up to now. Thus, the purpose of the present study was to evaluate plasma levels of BDNF of leprosy patients in comparison with non-infected individuals and at different stages of multidrug therapy (MDT), assessing its potential as a biomarker of nerve injury. Data collection started after the project was approved by the Committee of Ethics in Research of two hospitals: the Eduardo de Menezes Hospital and the Santa Casa de Misericordia of Belo Horizonte. All the subjects gave their informed consent to participate. Diagnosis and classification of leprosy were based on clinical assessment by taking a detailed history, careful medical and dermatological examination and detection of acid-fast bacilli in skin slit smears by an experienced technician. All leprosy patients but four were not classified as multibacillary according to the operational criteria of the World Health Organization 21 .
METHOD
Only patients who showed a positive response to treatment with complete clinical remission were included in this study, preventing any confounding effect due to lack of response to treatment. No patient developed leprosy reactions in the follow-up of treatment.
Non-infected (NI) individuals comprised age and gender-matched individuals (median age, years [range]: 46.5 ; sex M/F: 17/13). NI group was composed by healthy members of the community.
In leprosy patients, blood collection occurred four times (pre-treatment; 2 nd dose of MDT; 6 th dose and post-MDT); in healthy controls it occurred once. The number of patients submitted to peripheral blood collection at intermediate doses (i.e. 2 nd and 6 th doses) was lower than the number of samples at pre and post-treatment due to non-attendance of some patients. After blood centrifugation, plasma was collected and stored until analysis. Plasma levels of BDNF levels were measured by sandwich ELISA following the protocol provided by the manufacturer (R&D Systems, Minneapolis, USA). Concentration of BDNF was expressed in pg/ml.
For data analyses, the following methods were used: measures of central tendency and variability; the MannWhitney statistical tests for comparing BDNF levels in leprosy cases in pre-treatment and healthy controls; Wilcoxon test for comparing molecule levels in leprosy patients in pre-MDT and other treatment stages; and the generalized linear model (GLM) for repeated measures with four factors (F test), for comparing the kinetics of BDNF levels along treatment. GLM was restricted due to the small size of the sample, as only seven patients had their BDNF levels measured at all time points (pre-MDT, 2 nd dose, 6 th dose and post-MDT). In addition, a dispersion graph was used to assess the association between the BDNF levels in leprosy patients in the pre-and post-MDT and the number of affected nerves. The significance level adopted was 5%. 
RESULTS
Most patients were male, with a mean age of 50 years, and had more than five skin lesions and more than one nerve affected. Most patients were classified as multibacillary (MB), while 37.8% were positive at bacilloscopy.
BDNF levels were decreased in leprosy patients before treatment in comparison with the healthy controls, but this difference did not reach statistical difference (Fig 1) .
With regard to BDNF levels in leprosy patients in pretreatment and other periods (2 nd dose, 6 th dose and post-MDT), a significant difference was found only between pre-treatment and 2 nd dose (Fig 2) . The F-test, involving a sample of 7 leprosy patients who had their blood collected all time points, showed no significant difference in BDNF levels along the study, but graphic analysis revealed reduced BDNF levels after the beginning of treatment, with a tendency to recover with time (Fig 3) . In addition, dispersion graph showed no significant association between BDNF levels and the number of affected nerves (Fig 4) .
DISCUSSION
Although leprosy is known as a disease that damages peripheral nerves, little is known about the exact mechanism of the resulting neuropathy. As a consequence, much effort has been made to investigate possible neural markers of the disease [20] [21] [22] [23] . BDNF is expressed by numerous cells and tissues, including Schwann cells, playing a relevant role in neural development and plasticity. It is known that most indi- viduals can maintain constant BDNF levels when they become adults 24 . Therefore nerve damage following leprosy infection combined with other factors, such as the stress related to the stigma surrounding the disease, could result in decreased levels of BDNF in patients. Nevertheless, the present study showed no significant difference in BDNF levels between leprosy patients and healthy controls, giving no support to this hypothesis.
The comparison between BDNF pre-treatment levels and the other time points showed a significant difference only between pre-treatment and MDT 2 nd dose levels. The reduction of BDNF levels following the onset of MDT may result from the massive death of M. leprae bacilli and the associated Schwann cells lesion. When the kinetic of BDNF levels was analyzed along different phases of MDT in a subgroup of patients, no significant difference was found, but BDNF also decreased after the beginning of treatment. Interestingly, following this decline, BDNF level tends to increase with time, showing a tendency to recover its baseline level after MDT completion. This result must be seen as preliminary as only few patients had their samples collected at all time points. Further studies involving more patients and with a longer follow-up are necessary to confirm this.
The subclinical loss of nerve function, both sensory and mixed, is largely described in the literature, but there is a great need of search for reliable markers in early diagnosis and follow-up [25] [26] [27] [28] . Previous studies have investigated the value of different approaches such as systematic clinical evaluation of nerve function, electrophysiology and immunohistochemistry [25] [26] [27] . Clinical examination using the Semmes-Weinstein monofilament shows great sensitivity and specificity in nerve monitoring 27 . The neuromodulatory action of BDNF has been proposed in models of inflammation, peripheral nerve injury and neuropathic pain 29, 30 . No statistically significant difference was found to confirm the possible association between the BDNF levels and the number of nerves affected. This can be attributed to subjectivity (or examinerdependency) in the criterion for the evaluation of nerve damage, which has already been excluded from the classification of clinical forms of Hansen's disease.
In addition, factors with which it cannot interfere, such as genetic, nutritional status and likely the parallel use of other drugs may constitute limiting factors to infer conclusions about the results presented.
There are some other limitations in the present study that should be mentioned. One of them is the classification of patients based solely on clinical parameters. The classification of patients according to the Ridley-Jopling criteria was not possible because biopsy specimens are not routinely obtained in most regions where the disease is endemic. A careful clinical observation, by monitoring disease progression during treatment, often allows for the correction of errors in the initial classification, even when it is backed by laboratory data patterns considered, such as skin biopsy 28 . Another one is the size sample. These tenets need to be addressed in further studies.
In conclusion, our data suggest that BDNF may not be useful as a biomarker of neuropathy associated with leprosy. This study was the pioneer of a line of research involving neurotrophins in leprosy, which claims to evaluate their expression and function in leprotic neuritis and in reactional episodes, in order to confirm their presence as a predictive marker and a parameter for monitoring the patients' neural affection in future clinical trials. Moreover, the understanding of the biology of neurotrophins can contribute to the possible adoption of new therapeutic approaches.
